8-K filing — Acurx Pharmaceuticals, Inc. (ACXP)
Filed: 2026-10-29 AccNo: 0001104659-26-120279 Size: 197 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Acurx Pharmaceuticals Announces Publication of Preclinical Data on Oral Pol IIIC Inhibitors
Acurx Pharmaceuticals published preclinical data in ASM Spectrum demonstrating that its oral DNA polymerase IIIC inhibitors exhibit in vivo activity and microbiome-sparing effects compared to linezolid.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026
Acurx Pharmaceuticals has scheduled a conference call for November 12, 2026, to discuss its third-quarter 2026 financial results and provide a business update.
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target
Acurx Pharmaceuticals Says First Patient Enrolled In New PATHFINDER Clinical Trial In Patients With Multiply Recurrent C. Difficile Infection
PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in
Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call
Acurx Pharmaceuticals (NASDAQ:ACXP) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access
Acurx Pharmaceuticals Files Prospectus For 1.5M Offering